This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apricus Biosciences To Present At The 25th Annual ROTH Conference

SAN DIEGO, March 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( www.apricusbio.com ) announced today that Steve Martin, Interim Chief Executive Officer and Chief Financial Officer, will present at the 25th Annual ROTH Conference, being held at The Ritz Carlton in Dana Point, CA. Mr. Martin's presentation will take place on Monday, March 18, 2013 at 4:00 p.m. Pacific Time.

The presentation will be webcast and accessible to the public online at http://wsw.com/webcast/roth27/apri/ or via the Company's website at http://www.apricusbio.com . A replay will be available for 90 days after the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one 400-patient Phase III study in China.

For further information on Apricus Bio, visit http://www.apricusbio.com . You can also receive information at http://twitter.com/apricusbio .

CONTACT: Apricus Bio Investor Relations:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Apricus logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs